1
|
Shaprova ON, Shanshin DV, Kolosova EA, Borisevich SS, Soroka AA, Merkuleva IA, Nikitin AO, Volosnikova EA, Ushkalenko ND, Zaykovskaya AV, Pyankov OV, Elchaninova SA, Shcherbakov DN, Ilyicheva TN. Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2 among Siberian Populations. Antibodies (Basel) 2023; 12:82. [PMID: 38131804 PMCID: PMC10741209 DOI: 10.3390/antib12040082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Revised: 11/20/2023] [Accepted: 12/01/2023] [Indexed: 12/23/2023] Open
Abstract
In December 2019, a new coronavirus, SARS-CoV-2, was found to in Wuhan, China. Cases of infection were subsequently detected in other countries in a short period of time, resulting in the declaration of the COVID-19 pandemic by the World Health Organization (WHO) on 11 March 2020. Questions about the impact of herd immunity of pre-existing immune reactivity to SARS-CoV-2 on COVID-19 severity, associated with the immunity to seasonal manifestation, are still to be resolved and may be useful for understanding some processes that precede the emergence of a pandemic virus. Perhaps this will contribute to understanding some of the processes that precede the emergence of a pandemic virus. We assessed the specificity and virus-neutralizing capacity of antibodies reacting with the nucleocapsid and spike proteins of SARS-CoV-2 in a set of serum samples collected in October and November 2019, before the first COVID-19 cases were documented in this region. Blood serum samples from 799 residents of several regions of Siberia, Russia, (the Altai Territory, Irkutsk, Kemerovo and Novosibirsk regions, the Republic of Altai, Buryatia, and Khakassia) were analyzed. Sera of non-infected donors were collected within a study of seasonal influenza in the Russian Federation. The sample collection sites were located near the flyways and breeding grounds of wild waterfowl. The performance of enzyme-linked immunosorbent assay (ELISA) for the collected sera included the usage of recombinant SARS-CoV-2 protein antigens: full-length nucleocapsid protein (CoVN), receptor binding domain (RBD) of S-protein and infection fragment of the S protein (S5-6). There were 183 (22.9%) sera reactive to the S5-6, 270 (33.8%) sera corresponding to the full-length N protein and 128 (16.2%) sera simultaneously reactive to both these proteins. Only 5 out of 799 sera had IgG antibodies reactive to the RBD. None of the sera exhibited neutralizing activity against the nCoV/Victoria/1/2020 SARS-CoV-2 strain in Vero E6 cell culture. The data obtained in this study suggest that some of the population of the analyzed regions of Russia had cross-reactive humoral immunity against SARS-CoV-2 before the COVID-19 pandemic started. Moreover, among individuals from relatively isolated regions, there were significantly fewer reliably cross-reactive sera. The possible significance of these data and impact of cross-immunity to SARS-CoV-2 on the prevalence and mortality of COVID-19 needs further assessment.
Collapse
Affiliation(s)
- Olga N. Shaprova
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (O.N.S.); (D.V.S.); (I.A.M.); (A.O.N.); (E.A.V.); (N.D.U.); (A.V.Z.); (O.V.P.); (D.N.S.); (T.N.I.)
| | - Daniil V. Shanshin
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (O.N.S.); (D.V.S.); (I.A.M.); (A.O.N.); (E.A.V.); (N.D.U.); (A.V.Z.); (O.V.P.); (D.N.S.); (T.N.I.)
- Russian-American Anti-Cancer Center, Altai State University, 656049 Barnaul, Russia
| | - Evgeniia A. Kolosova
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (O.N.S.); (D.V.S.); (I.A.M.); (A.O.N.); (E.A.V.); (N.D.U.); (A.V.Z.); (O.V.P.); (D.N.S.); (T.N.I.)
- Russian-American Anti-Cancer Center, Altai State University, 656049 Barnaul, Russia
| | - Sophia S. Borisevich
- Laboratory of Chemical Physics, Ufa Institute of Chemistry Ufa Federal Research Center, 450078 Ufa, Russia;
- Institute of Intelligent Cybernetic Systems, National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), 115409 Moscow, Russia;
| | - Artem A. Soroka
- Institute of Intelligent Cybernetic Systems, National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), 115409 Moscow, Russia;
| | - Iuliia A. Merkuleva
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (O.N.S.); (D.V.S.); (I.A.M.); (A.O.N.); (E.A.V.); (N.D.U.); (A.V.Z.); (O.V.P.); (D.N.S.); (T.N.I.)
| | - Artem O. Nikitin
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (O.N.S.); (D.V.S.); (I.A.M.); (A.O.N.); (E.A.V.); (N.D.U.); (A.V.Z.); (O.V.P.); (D.N.S.); (T.N.I.)
| | - Ekaterina A. Volosnikova
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (O.N.S.); (D.V.S.); (I.A.M.); (A.O.N.); (E.A.V.); (N.D.U.); (A.V.Z.); (O.V.P.); (D.N.S.); (T.N.I.)
| | - Nikita D. Ushkalenko
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (O.N.S.); (D.V.S.); (I.A.M.); (A.O.N.); (E.A.V.); (N.D.U.); (A.V.Z.); (O.V.P.); (D.N.S.); (T.N.I.)
| | - Anna V. Zaykovskaya
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (O.N.S.); (D.V.S.); (I.A.M.); (A.O.N.); (E.A.V.); (N.D.U.); (A.V.Z.); (O.V.P.); (D.N.S.); (T.N.I.)
| | - Oleg V. Pyankov
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (O.N.S.); (D.V.S.); (I.A.M.); (A.O.N.); (E.A.V.); (N.D.U.); (A.V.Z.); (O.V.P.); (D.N.S.); (T.N.I.)
| | - Svetlana A. Elchaninova
- Department of Biochemistry and Clinical Laboratory Diagnostics, Altai State Medical University, 656038 Barnaul, Russia;
| | - Dmitry N. Shcherbakov
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (O.N.S.); (D.V.S.); (I.A.M.); (A.O.N.); (E.A.V.); (N.D.U.); (A.V.Z.); (O.V.P.); (D.N.S.); (T.N.I.)
- Russian-American Anti-Cancer Center, Altai State University, 656049 Barnaul, Russia
| | - Tatiana N. Ilyicheva
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia; (O.N.S.); (D.V.S.); (I.A.M.); (A.O.N.); (E.A.V.); (N.D.U.); (A.V.Z.); (O.V.P.); (D.N.S.); (T.N.I.)
| |
Collapse
|
2
|
Belenkaya SV, Merkuleva IA, Yarovaya OI, Chirkova VY, Sharlaeva EA, Shanshin DV, Volosnikova EA, Vatsadze SZ, Khvostov MV, Salakhutdinov NF, Shcherbakov D. Corrigendum: The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper. Front Bioeng Biotechnol 2023; 11:1294266. [PMID: 38026885 PMCID: PMC10658891 DOI: 10.3389/fbioe.2023.1294266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Accepted: 10/03/2023] [Indexed: 12/01/2023] Open
Abstract
[This corrects the article DOI: 10.3389/fbioe.2023.1187761.].
Collapse
Affiliation(s)
- Svetlana V. Belenkaya
- Laboratory of Bionanotechnology, Microbiology and Virology, Novosibirsk State University, Novosibirsk, Russia
- State Research Center of Virology and Biotechnology VECTOR, Koltsovo, Russia
- Department of Medicinal Chemistry, N.N Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Novosibirsk, Russia
| | - Iuliia A. Merkuleva
- State Research Center of Virology and Biotechnology VECTOR, Koltsovo, Russia
| | - Olga I. Yarovaya
- Laboratory of Bionanotechnology, Microbiology and Virology, Novosibirsk State University, Novosibirsk, Russia
- Department of Medicinal Chemistry, N.N Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Novosibirsk, Russia
| | - Varvara Yu Chirkova
- Department of Physical-Chemistry Biology and Biotechnology, Altay State University, Barnaul, Russia
| | - Elena A. Sharlaeva
- Department of Physical-Chemistry Biology and Biotechnology, Altay State University, Barnaul, Russia
| | - Daniil V. Shanshin
- State Research Center of Virology and Biotechnology VECTOR, Koltsovo, Russia
| | | | - Sergey Z. Vatsadze
- N.D Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - Mikhail V. Khvostov
- Department of Medicinal Chemistry, N.N Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Novosibirsk, Russia
| | - Nariman F. Salakhutdinov
- Department of Medicinal Chemistry, N.N Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Novosibirsk, Russia
| | - Dmitriy Shcherbakov
- State Research Center of Virology and Biotechnology VECTOR, Koltsovo, Russia
- Department of Medicinal Chemistry, N.N Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Novosibirsk, Russia
- Department of Physical-Chemistry Biology and Biotechnology, Altay State University, Barnaul, Russia
| |
Collapse
|
3
|
Kudrov GA, Zainutdinov SS, Grazhdantseva AA, Shipovalov AV, Sivolobova GF, Semenova AV, Merkuleva IA, Shcherbakov DN, Taranov OS, Zaykovskaya AV, Shulgina IS, Pyankov OV, Kochneva GV. [Intranasal vaccine against COVID-19 based on a recombinant variant of the Sendai virus (Paramyxoviridae: Respirovirus) strain Moscow]. Vopr Virusol 2023; 68:215-227. [PMID: 37436413 DOI: 10.36233/0507-4088-172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2023] [Indexed: 07/13/2023]
Abstract
INTRODUCTION Intranasal vaccination using live vector vaccines based on non-pathogenic or slightly pathogenic viruses is the one of the most convenient, safe and effective ways to prevent respiratory infections, including COVID-19. Sendai virus is the best suited for this purpose, since it is respiratory virus and is capable of limited replication in human bronchial epithelial cells without causing disease. The aim of the work is to design and study the vaccine properties of recombinant Sendai virus, Moscow strain, expressing secreted receptor-binding domain of SARS-CoV-2 Delta strain S protein (RBDdelta) during a single intranasal immunization. MATERIALS AND METHODS Recombinant Sendai virus carrying insertion of RBDdelta transgene between P and M genes was constructed using reverse genetics and synthetic biology methods. Expression of RBDdelta was analyzed by Western blot. Vaccine properties were studied in two models: Syrian hamsters and BALB/c mice. Immunogenicity was evaluated by ELISA and virus-neutralization assays. Protectiveness was assessed by quantitation of SARS-CoV-2 RNA in RT-PCR and histological analysis of the lungs. RESULTS Based on Sendai virus Moscow strain, a recombinant Sen-RBDdelta(M) was constructed that expressed a secreted RBDdelta immunologically identical to natural SARS-CoV-2 protein. A single intranasal administration of Sen-RBDdelta(M) to hamsters and mice significantly, by 15 and 107 times, respectively, reduced replicative activity of SARS-CoV-2 in lungs of animals, preventing the development of pneumonia. An effective induction of virus-neutralizing antibodies has also been demonstrated in mice. CONCLUSION Sen-RBDdelta(M) is a promising vaccine construct against SARS-CoV-2 infection and has a protective properties even after a single intranasal introduction.
Collapse
Affiliation(s)
- G A Kudrov
- State Research Center of Virology and Biotechnology "Vector" of Rospotrebnadzor
| | - S S Zainutdinov
- State Research Center of Virology and Biotechnology "Vector" of Rospotrebnadzor
| | - A A Grazhdantseva
- State Research Center of Virology and Biotechnology "Vector" of Rospotrebnadzor
| | - A V Shipovalov
- State Research Center of Virology and Biotechnology "Vector" of Rospotrebnadzor
| | - G F Sivolobova
- State Research Center of Virology and Biotechnology "Vector" of Rospotrebnadzor
| | - A V Semenova
- State Research Center of Virology and Biotechnology "Vector" of Rospotrebnadzor
| | - I A Merkuleva
- State Research Center of Virology and Biotechnology "Vector" of Rospotrebnadzor
| | - D N Shcherbakov
- State Research Center of Virology and Biotechnology "Vector" of Rospotrebnadzor
| | - O S Taranov
- State Research Center of Virology and Biotechnology "Vector" of Rospotrebnadzor
| | - A V Zaykovskaya
- State Research Center of Virology and Biotechnology "Vector" of Rospotrebnadzor
| | - I S Shulgina
- State Research Center of Virology and Biotechnology "Vector" of Rospotrebnadzor
| | - O V Pyankov
- State Research Center of Virology and Biotechnology "Vector" of Rospotrebnadzor
| | - G V Kochneva
- State Research Center of Virology and Biotechnology "Vector" of Rospotrebnadzor
| |
Collapse
|
4
|
Belenkaya SV, Merkuleva IA, Yarovaya OI, Chirkova VY, Sharlaeva EA, Shanshin DV, Volosnikova EA, Vatsadze SZ, Khvostov MV, Salakhutdinov NF, Shcherbakov DN. The main protease 3CLpro of the SARS-CoV-2 virus: how to turn an enemy into a helper. Front Bioeng Biotechnol 2023; 11:1187761. [PMID: 37456729 PMCID: PMC10345205 DOI: 10.3389/fbioe.2023.1187761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2023] [Accepted: 06/21/2023] [Indexed: 07/18/2023] Open
Abstract
Despite the long history of use and the knowledge of the genetics and biochemistry of E. coli, problems are still possible in obtaining a soluble form of recombinant proteins in this system. Although, soluble protein can be obtained both in the cytoplasm and in the periplasm of the bacterial cell. The latter is a priority strategy for obtaining soluble proteins. The fusion protein technology followed by detachment of the fusion protein with proteases is used to transfer the target protein into the periplasmic space of E. coli. We have continued for the first time to use the main viral protease 3CL of the SARS-CoV-2 virus for this purpose. We obtained a recombinant 3CL protease and studied its complex catalytic properties. The authenticity of the resulting recombinant enzyme, were confirmed by specific activity analysis and activity suppression by the known low-molecular-weight inhibitors. The catalytic efficiency of 3CL (0.17 ± 0.02 µM-1-s-1) was shown to be one order of magnitude higher than that of the widely used tobacco etch virus protease (0.013 ± 0.003 µM-1-s-1). The application of the 3CL gene in genetically engineered constructs provided efficient specific proteolysis of fusion proteins, which we demonstrated using the receptor-binding domain of SARS-CoV-2 spike protein and GST fusion protein. The solubility and immunochemical properties of RBD were preserved. It is very important that in work we have shown that 3CL protease works effectively directly in E. coli cells when co-expressed with the target fusion protein, as well as when expressed as part of a chimeric protein containing the target protein, fusion partner, and 3CL itself. The results obtained in the work allow expanding the repertoire of specific proteases for researchers and biotechnologists.
Collapse
Affiliation(s)
- Svetlana V. Belenkaya
- Laboratory of Bionanotechnology, Microbiology and Virology, Novosibirsk State University, Novosibirsk, Russia
- State Research Center of Virology and Biotechnology VECTOR, Koltsovo, Russia
- Department of Medicinal Chemistry, N.N Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Novosibirsk, Russia
| | - Iuliia A. Merkuleva
- State Research Center of Virology and Biotechnology VECTOR, Koltsovo, Russia
| | - Olga I. Yarovaya
- Laboratory of Bionanotechnology, Microbiology and Virology, Novosibirsk State University, Novosibirsk, Russia
- Department of Medicinal Chemistry, N.N Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Novosibirsk, Russia
| | - Varvara Yu. Chirkova
- Department of Physical-Chemistry Biology and Biotechnology, Altay State University, Barnaul, Russia
| | - Elena A. Sharlaeva
- Department of Physical-Chemistry Biology and Biotechnology, Altay State University, Barnaul, Russia
| | - Daniil V. Shanshin
- State Research Center of Virology and Biotechnology VECTOR, Koltsovo, Russia
| | | | - Sergey Z. Vatsadze
- N.D Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - Mikhail V. Khvostov
- Department of Medicinal Chemistry, N.N Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Novosibirsk, Russia
| | - Nariman F. Salakhutdinov
- Department of Medicinal Chemistry, N.N Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Novosibirsk, Russia
| | - Dmitriy N. Shcherbakov
- State Research Center of Virology and Biotechnology VECTOR, Koltsovo, Russia
- Department of Medicinal Chemistry, N.N Vorozhtsov Novosibirsk Institute of Organic Chemistry SB RAS, Novosibirsk, Russia
- Department of Physical-Chemistry Biology and Biotechnology, Altay State University, Barnaul, Russia
| |
Collapse
|
5
|
Volosnikova EA, Merkuleva IA, Esina TI, Shcherbakov DN, Borgoyakova MB, Isaeva AA, Nesmeyanova VS, Volkova NV, Belenkaya SV, Zaykovskaya AV, Pyankov OV, Starostina EV, Zadorozhny AM, Zaitsev BN, Karpenko LI, Ilyichev AA, Danilenko ED. SARS-CoV-2 RBD Conjugated to Polyglucin, Spermidine, and dsRNA Elicits a Strong Immune Response in Mice. Vaccines (Basel) 2023; 11:vaccines11040808. [PMID: 37112720 PMCID: PMC10146165 DOI: 10.3390/vaccines11040808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2023] [Revised: 03/31/2023] [Accepted: 04/04/2023] [Indexed: 04/29/2023] Open
Abstract
Despite the rapid development and approval of several COVID vaccines based on the full-length spike protein, there is a need for safe, potent, and high-volume vaccines. Considering the predominance of the production of neutralizing antibodies targeting the receptor-binding domain (RBD) of S-protein after natural infection or vaccination, it makes sense to choose RBD as a vaccine immunogen. However, due to its small size, RBD exhibits relatively poor immunogenicity. Searching for novel adjuvants for RBD-based vaccine formulations is considered a good strategy for enhancing its immunogenicity. Herein, we assess the immunogenicity of severe acute respiratory syndrome coronavirus 2 RBD conjugated to a polyglucin:spermidine complex (PGS) and dsRNA (RBD-PGS + dsRNA) in a mouse model. BALB/c mice were immunized intramuscularly twice, with a 2-week interval, with 50 µg of RBD, RBD with Al(OH)3, or conjugated RBD. A comparative analysis of serum RBD-specific IgG and neutralizing antibody titers showed that PGS, PGS + dsRNA, and Al(OH)3 enhanced the specific humoral response in animals. There was no significant difference between the groups immunized with RBD-PGS + dsRNA and RBD with Al(OH)3. Additionally, the study of the T-cell response in animals showed that, unlike adjuvants, the RBD-PGS + dsRNA conjugate stimulates the production of specific CD4+ and CD8+ T cells in animals.
Collapse
Affiliation(s)
- Ekaterina A Volosnikova
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Iuliia A Merkuleva
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Tatiana I Esina
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Dmitry N Shcherbakov
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Mariya B Borgoyakova
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Anastasiya A Isaeva
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Valentina S Nesmeyanova
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Natalia V Volkova
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Svetlana V Belenkaya
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Anna V Zaykovskaya
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Oleg V Pyankov
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Ekaterina V Starostina
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Alexey M Zadorozhny
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Boris N Zaitsev
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Larisa I Karpenko
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Alexander A Ilyichev
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| | - Elena D Danilenko
- State Research Center of Virology and Biotechnology VECTOR, Rospotrebnadzor, 630559 Koltsovo, Russia
| |
Collapse
|
6
|
Timofeeva AM, Sedykh SE, Ermakov EA, Matveev AL, Odegova EI, Sedykh TA, Shcherbakov DN, Merkuleva IA, Volosnikova EA, Nesmeyanova VS, Tikunova NV, Nevinsky GA. Natural IgG against S-Protein and RBD of SARS-CoV-2 Do Not Bind and Hydrolyze DNA and Are Not Autoimmune. Int J Mol Sci 2022; 23:ijms232213681. [PMID: 36430159 PMCID: PMC9693483 DOI: 10.3390/ijms232213681] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 11/01/2022] [Accepted: 11/03/2022] [Indexed: 11/10/2022] Open
Abstract
Since the onset of the COVID-19 pandemic, numerous publications have appeared describing autoimmune pathologies developing after a coronavirus infection, with several papers reporting autoantibody production during the acute period of the disease. Several viral diseases are known to trigger autoimmune processes, and the appearance of catalytic antibodies with DNase activity is one of the earliest markers of several autoimmune pathologies. Therefore, we analyzed whether IgG antibodies from blood plasma of SARS-CoV-2 patients after recovery could bind and hydrolyze DNA. We analyzed how vaccination of patients with adenovirus Sputnik V vaccine influences the production of abzymes with DNase activity. Four groups were selected for the analysis, each containing 25 patients according to their relative titers of antibodies to S-protein: with high and median titers, vaccinated with Sputnik V with high titers, and a control group of donors with negative titers. The relative titers of antibodies against DNA and the relative DNase activity of IgGs depended very much on the individual patient and the donor, and no significant correlation was found between the relative values of antibodies titers and their DNase activity. Our results indicate that COVID-19 disease and vaccination with adenoviral Sputnik V vaccine do not result in the development or enhancement of strong autoimmune reactions as in the typical autoimmune diseases associated with the production of anti-DNA and DNA hydrolyzing antibodies.
Collapse
Affiliation(s)
- Anna M. Timofeeva
- SB RAS Institute of Chemical Biology and Fundamental Medicine, 630090 Novosibirsk, Russia
- Correspondence:
| | - Sergey E. Sedykh
- SB RAS Institute of Chemical Biology and Fundamental Medicine, 630090 Novosibirsk, Russia
- Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia
| | - Evgeny A. Ermakov
- SB RAS Institute of Chemical Biology and Fundamental Medicine, 630090 Novosibirsk, Russia
- Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia
| | - Andrey L. Matveev
- SB RAS Institute of Chemical Biology and Fundamental Medicine, 630090 Novosibirsk, Russia
| | - Eva I. Odegova
- SB RAS Institute of Chemical Biology and Fundamental Medicine, 630090 Novosibirsk, Russia
| | - Tatiana A. Sedykh
- SB RAS Institute of Chemical Biology and Fundamental Medicine, 630090 Novosibirsk, Russia
| | - Dmitry N. Shcherbakov
- State Research Center of Virology and Biotechnology Vector, 630559 Koltsovo, Russia
- Department of Physical-Chemistry Biology and Biotechnology, Altay State University, 656049 Barnaul, Russia
| | - Iuliia A. Merkuleva
- State Research Center of Virology and Biotechnology Vector, 630559 Koltsovo, Russia
| | | | | | - Nina V. Tikunova
- SB RAS Institute of Chemical Biology and Fundamental Medicine, 630090 Novosibirsk, Russia
- Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia
| | - Georgy A. Nevinsky
- SB RAS Institute of Chemical Biology and Fundamental Medicine, 630090 Novosibirsk, Russia
- Faculty of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia
| |
Collapse
|
7
|
Merkuleva IA, Shcherbakov DN, Borgoyakova MB, Isaeva AA, Nesmeyanova VS, Volkova NV, Aripov VS, Shanshin DV, Karpenko LI, Belenkaya SV, Kazachinskaia EI, Volosnikova EA, Esina TI, Sergeev AA, Titova KA, Konyakhina YV, Zaykovskaya AV, Pyankov OV, Kolosova EA, Viktorina OE, Shelemba AA, Rudometov AP, Ilyichev AA. Are Hamsters a Suitable Model for Evaluating the Immunogenicity of RBD-Based Anti-COVID-19 Subunit Vaccines? Viruses 2022; 14:v14051060. [PMID: 35632800 PMCID: PMC9146860 DOI: 10.3390/v14051060] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2022] [Revised: 05/07/2022] [Accepted: 05/13/2022] [Indexed: 02/01/2023] Open
Abstract
Currently, SARS-CoV-2 spike receptor-binding-domain (RBD)-based vaccines are considered one of the most effective weapons against COVID-19. During the first step of assessing vaccine immunogenicity, a mouse model is often used. In this paper, we tested the use of five experimental animals (mice, hamsters, rabbits, ferrets, and chickens) for RBD immunogenicity assessments. The humoral immune response was evaluated by ELISA and virus-neutralization assays. The data obtained show hamsters to be the least suitable candidates for RBD immunogenicity testing and, hence, assessing the protective efficacy of RBD-based vaccines.
Collapse
Affiliation(s)
- Iuliia A. Merkuleva
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Dmitry N. Shcherbakov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
- Correspondence: ; Tel.: +7-383-363-47-00 (ext. 2007)
| | - Mariya B. Borgoyakova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Anastasiya A. Isaeva
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Valentina S. Nesmeyanova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Natalia V. Volkova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Vazirbek S. Aripov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Daniil V. Shanshin
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Larisa I. Karpenko
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Svetlana V. Belenkaya
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Elena I. Kazachinskaia
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Ekaterina A. Volosnikova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Tatiana I. Esina
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Alexandr A. Sergeev
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Kseniia A. Titova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Yulia V. Konyakhina
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Anna V. Zaykovskaya
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Oleg V. Pyankov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Evgeniia A. Kolosova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
- Russian-American Anti-Cancer Center, Altai State University, 656049 Barnaul, Russia;
| | - Olesya E. Viktorina
- Russian-American Anti-Cancer Center, Altai State University, 656049 Barnaul, Russia;
| | - Arseniya A. Shelemba
- Federal Research Center of Fundamental and Translational Medicine, 630060 Novosibirsk, Russia;
| | - Andrey P. Rudometov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| | - Alexander A. Ilyichev
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Koltsovo, Russia; (I.A.M.); (M.B.B.); (A.A.I.); (V.S.N.); (N.V.V.); (V.S.A.); (D.V.S.); (L.I.K.); (S.V.B.); (E.I.K.); (E.A.V.); (T.I.E.); (A.A.S.); (K.A.T.); (Y.V.K.); (A.V.Z.); (O.V.P.); (E.A.K.); (A.P.R.); (A.A.I.)
| |
Collapse
|
8
|
Mironov V, Shchugoreva IA, Artyushenko PV, Morozov D, Borbone N, Oliviero G, Zamay TN, Moryachkov RV, Kolovskaya OS, Lukyanenko KA, Song Y, Merkuleva IA, Zabluda VN, Peters G, Koroleva LS, Veprintsev DV, Glazyrin YE, Volosnikova EA, Belenkaya SV, Esina TI, Isaeva AA, Nesmeyanova VS, Shanshin DV, Berlina AN, Komova NS, Svetlichnyi VA, Silnikov VN, Shcherbakov DN, Zamay GS, Zamay SS, Smolyarova T, Tikhonova EP, Chen KH, Jeng U, Condorelli G, de Franciscis V, Groenhof G, Yang C, Moskovsky AA, Fedorov DG, Tomilin FN, Tan W, Alexeev Y, Berezovski MV, Kichkailo AS. Cover Feature: Structure‐ and Interaction‐Based Design of Anti‐SARS‐CoV‐2 Aptamers (Chem. Eur. J. 12/2022). Chemistry 2022. [PMCID: PMC9086947 DOI: 10.1002/chem.202200378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
9
|
Mironov V, Shchugoreva IA, Artyushenko PV, Morozov D, Borbone N, Oliviero G, Zamay TN, Moryachkov RV, Kolovskaya OS, Lukyanenko KA, Song Y, Merkuleva IA, Zabluda VN, Peters G, Koroleva LS, Veprintsev DV, Glazyrin YE, Volosnikova EA, Belenkaya SV, Esina TI, Isaeva AA, Nesmeyanova VS, Shanshin DV, Berlina AN, Komova NS, Svetlichnyi VA, Silnikov VN, Shcherbakov DN, Zamay GS, Zamay SS, Smolyarova T, Tikhonova EP, Chen KH, Jeng U, Condorelli G, de Franciscis V, Groenhof G, Yang C, Moskovsky AA, Fedorov DG, Tomilin FN, Tan W, Alexeev Y, Berezovski MV, Kichkailo AS. Structure- and Interaction-Based Design of Anti-SARS-CoV-2 Aptamers. Chemistry 2022; 28:e202104481. [PMID: 35025110 PMCID: PMC9015568 DOI: 10.1002/chem.202104481] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Indexed: 11/10/2022]
Abstract
Aptamer selection against novel infections is a complicated and time-consuming approach. Synergy can be achieved by using computational methods together with experimental procedures. This study aims to develop a reliable methodology for a rational aptamer in silico et vitro design. The new approach combines multiple steps: (1) Molecular design, based on screening in a DNA aptamer library and directed mutagenesis to fit the protein tertiary structure; (2) 3D molecular modeling of the target; (3) Molecular docking of an aptamer with the protein; (4) Molecular dynamics (MD) simulations of the complexes; (5) Quantum-mechanical (QM) evaluation of the interactions between aptamer and target with further analysis; (6) Experimental verification at each cycle for structure and binding affinity by using small-angle X-ray scattering, cytometry, and fluorescence polarization. By using a new iterative design procedure, structure- and interaction-based drug design (SIBDD), a highly specific aptamer to the receptor-binding domain of the SARS-CoV-2 spike protein, was developed and validated. The SIBDD approach enhances speed of the high-affinity aptamers development from scratch, using a target protein structure. The method could be used to improve existing aptamers for stronger binding. This approach brings to an advanced level the development of novel affinity probes, functional nucleic acids. It offers a blueprint for the straightforward design of targeting molecules for new pathogen agents and emerging variants.
Collapse
|
10
|
Borgoyakova MB, Karpenko LI, Rudometov AP, Volosnikova EA, Merkuleva IA, Starostina EV, Zadorozhny AM, Isaeva AA, Nesmeyanova VS, Shanshin DV, Baranov KO, Volkova NV, Zaitsev BN, Orlova LA, Zaykovskaya AV, Pyankov OV, Danilenko ED, Bazhan SI, Shcherbakov DN, Taranin AV, Ilyichev AA. Self-Assembled Particles Combining SARS-CoV-2 RBD Protein and RBD DNA Vaccine Induce Synergistic Enhancement of the Humoral Response in Mice. Int J Mol Sci 2022; 23:2188. [PMID: 35216301 PMCID: PMC8876144 DOI: 10.3390/ijms23042188] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 02/13/2022] [Accepted: 02/13/2022] [Indexed: 12/23/2022] Open
Abstract
Despite the fact that a range of vaccines against COVID-19 have already been created and are used for mass vaccination, the development of effective, safe, technological, and affordable vaccines continues. We have designed a vaccine that combines the recombinant protein and DNA vaccine approaches in a self-assembled particle. The receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 was conjugated to polyglucin:spermidine and mixed with DNA vaccine (pVAXrbd), which led to the formation of particles of combined coronavirus vaccine (CCV-RBD) that contain the DNA vaccine inside and RBD protein on the surface. CCV-RBD particles were characterized with gel filtration, electron microscopy, and biolayer interferometry. To investigate the immunogenicity of the combined vaccine and its components, mice were immunized with the DNA vaccine pVAXrbd or RBD protein as well as CCV-RBD particles. The highest antigen-specific IgG and neutralizing activity were induced by CCV-RBD, and the level of antibodies induced by DNA or RBD alone was significantly lower. The cellular immune response was detected only in the case of DNA or CCV-RBD vaccination. These results demonstrate that a combination of DNA vaccine and RBD protein in one construct synergistically increases the humoral response to RBD protein in mice.
Collapse
Affiliation(s)
- Mariya B. Borgoyakova
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Larisa I. Karpenko
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Andrey P. Rudometov
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Ekaterina A. Volosnikova
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Iuliia A. Merkuleva
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Ekaterina V. Starostina
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Alexey M. Zadorozhny
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Anastasiya A. Isaeva
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Valentina S. Nesmeyanova
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Daniil V. Shanshin
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Konstantin O. Baranov
- Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Science, 630090 Novosibirsk, Russia; (K.O.B.); (A.V.T.)
| | - Natalya V. Volkova
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Boris N. Zaitsev
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Lyubov A. Orlova
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Anna V. Zaykovskaya
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Oleg V. Pyankov
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Elena D. Danilenko
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Sergei I. Bazhan
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Dmitry N. Shcherbakov
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| | - Alexander V. Taranin
- Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Science, 630090 Novosibirsk, Russia; (K.O.B.); (A.V.T.)
| | - Alexander A. Ilyichev
- State Research Center of Virology and Biotechnology “Vector”, 630559 Koltsovo, Novosibirsk Region, Russia; (M.B.B.); (A.P.R.); (E.A.V.); (I.A.M.); (E.V.S.); (A.M.Z.); (A.A.I.); (V.S.N.); (D.V.S.); (N.V.V.); (B.N.Z.); (L.A.O.); (A.V.Z.); (O.V.P.); (E.D.D.); (S.I.B.); (D.N.S.); (A.A.I.)
| |
Collapse
|
11
|
Merkuleva IA, Shcherbakov DN, Borgoyakova MB, Shanshin DV, Rudometov AP, Karpenko LI, Belenkaya SV, Isaeva AA, Nesmeyanova VS, Kazachinskaia EI, Volosnikova EA, Esina TI, Zaykovskaya AV, Pyankov OV, Borisevich SS, Shelemba AA, Chikaev AN, Ilyichev AA. Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems. Vaccines (Basel) 2022; 10:vaccines10010096. [PMID: 35062757 PMCID: PMC8779843 DOI: 10.3390/vaccines10010096] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2021] [Revised: 01/02/2022] [Accepted: 01/04/2022] [Indexed: 01/05/2023] Open
Abstract
The receptor-binding domain (RBD) of the protein S SARS-CoV-2 is considered to be one of the appealing targets for developing a vaccine against COVID-19. The choice of an expression system is essential when developing subunit vaccines, as it ensures the effective synthesis of the correctly folded target protein, and maintains its antigenic and immunogenic properties. Here, we describe the production of a recombinant RBD protein using prokaryotic (pRBD) and mammalian (mRBD) expression systems, and compare the immunogenicity of prokaryotic and mammalian-expressed RBD using a BALB/c mice model. An analysis of the sera from mice immunized with both variants of the protein revealed that the mRBD expressed in CHO cells provides a significantly stronger humoral immune response compared with the RBD expressed in E.coli cells. A specific antibody titer of sera from mice immunized with mRBD was ten-fold higher than the sera from the mice that received pRBD in ELISA, and about 100-fold higher in a neutralization test. The data obtained suggests that mRBD is capable of inducing neutralizing antibodies against SARS-CoV-2.
Collapse
Affiliation(s)
- Iuliia A. Merkuleva
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Dmitry N. Shcherbakov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
- Correspondence: ; Tel.: +7-383-363-47-00 (ext. 2007)
| | - Mariya B. Borgoyakova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Daniil V. Shanshin
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Andrey P. Rudometov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Larisa I. Karpenko
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Svetlana V. Belenkaya
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Anastasiya A. Isaeva
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Valentina S. Nesmeyanova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Elena I. Kazachinskaia
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Ekaterina A. Volosnikova
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Tatiana I. Esina
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Anna V. Zaykovskaya
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Oleg V. Pyankov
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| | - Sophia S. Borisevich
- Laboratory of Chemical Physics, Ufa Institute of Chemistry, Ufa Federal Research Center, 450078 Ufa, Russia;
| | - Arseniya A. Shelemba
- Federal Research Center of Fundamental and Translational Medicine, 630060 Novosibirsk, Russia;
| | - Anton N. Chikaev
- Institute of Molecular and Cellular Biology, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia;
| | - Alexander A. Ilyichev
- State Research Center of Virology and Biotechnology “Vector”, Rospotrebnadzor, World-Class Genomic Research Center for Biological Safety and Technological Independence, Federal Scientific and Technical Program on the Development of Genetic Technologies, 630559 Novosibirsk, Russia; (I.A.M.); (M.B.B.); (D.V.S.); (A.P.R.); (L.I.K.); (S.V.B.); (A.A.I.); (V.S.N.); (E.I.K.); (E.A.V.); (T.I.E.); (A.V.Z.); (O.V.P.); (A.A.I.)
| |
Collapse
|